Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03042312 · ClinicalTrials.gov registry record · Phase 2
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
A Phase 2 study, sponsored by Endocyte.
- Terminated
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT03042312: Clinical Trial Phase 2 study, sponsored by Endocyte.
NCT03042312 is a Phase 2 study that was terminated before completion, run by Endocyte. The registered enrollment target is 71 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03042312, a Phase 2 study, was terminated before completion, sponsored by Endocyte.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
This was an open-label, multicenter, prospective trial to assess safety and efficacy of 177Lu-PSMA-617 in patients with metastatic castration resistant prostate cancer.
Interventions
- DRUG 177Lu-PSMA-617
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2017-07-12 |
| Est. Completion | 2020-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03042312
The ClinicalTrials.gov registry entry for NCT03042312 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endocyte, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 177Lu-PSMA-617 is the first listed.
NCT03042312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03042312 about?
NCT03042312 is a clinical study titled "Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy". This was an open-label, multicenter, prospective trial to assess safety and efficacy of 177Lu-PSMA-617 in patients with metastatic castration resistant prostate cancer.
What is the current status of trial NCT03042312?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2017-07-12. Estimated completion is 2020-01-15.
What interventions are being tested in trial NCT03042312?
The interventions under investigation include: 177Lu-PSMA-617 (DRUG).
Who is sponsoring clinical trial NCT03042312?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.